KdT Ventures’ Post

KdT Ventures is back with another episode of The World in a Grain of Sand, where we break down an S1 filing from a biotech IPO and share insights on the science, business models, and financials. Ketan Yerneni and Mack Healy dig into Verve Therapeutics, a gene editing biotech tackling one of the most common chronic diseases: cardiovascular disease. they discuss: - base editing, and its advantages over traditional (potentially error-prone) CRISPR. - Verve’s approach for predicting off-target gene editing, a key challenge for the gene editing field. - Verve’s unique licensing strategy with Beam, Acuitas, and the Broad to secure several foundational technologies. - the competitive landscape and target product profile tradeoffs of one-and-done gene editing approaches vs other therapeutic modalities. and much more. check out the full episode in the comments.